Akero Therapeutics (AKRO) News Today $30.64 -0.39 (-1.26%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Akero Therapeutics (NASDAQ:AKRO) Research Coverage Started at CitigroupNovember 21 at 2:48 AM | americanbankingnews.comCatriona Yale Sells 9,061 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockNovember 20 at 5:47 AM | insidertrades.comHC Wainwright Reaffirms Buy Rating for Akero Therapeutics (NASDAQ:AKRO)November 20 at 1:55 AM | americanbankingnews.comAkero Therapeutics initiated with a Buy at CitiNovember 19 at 11:25 AM | markets.businessinsider.comAkero Therapeutics (AKRO) Receives a Buy from Phillip SecuritiesNovember 19 at 11:25 AM | markets.businessinsider.comCitigroup Initiates Coverage of Akero Therapeutics (AKRO) with Buy RecommendationNovember 19 at 11:25 AM | msn.comHC Wainwright Reaffirms "Buy" Rating for Akero Therapeutics (NASDAQ:AKRO)HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Akero Therapeutics in a research report on Monday.November 18 at 8:11 AM | marketbeat.comCitigroup Begins Coverage on Akero Therapeutics (NASDAQ:AKRO)Citigroup assumed coverage on shares of Akero Therapeutics in a research report on Monday. They issued a "buy" rating and a $65.00 price objective for the company.November 18 at 7:29 AM | marketbeat.comPromising Clinical Trial Results and Future Potential Justify Buy Rating for Akero TherapeuticsNovember 17, 2024 | markets.businessinsider.comAkero to showcase new analyses of Phase 2b HARMONY study at AASLDNovember 15, 2024 | markets.businessinsider.comAkero Therapeutics (NASDAQ:AKRO) Shares Down 6.4% - What's Next?Akero Therapeutics (NASDAQ:AKRO) Stock Price Down 6.4% - Here's WhyNovember 15, 2024 | marketbeat.comSimplify Asset Management Inc. Boosts Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)Simplify Asset Management Inc. increased its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 15.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 283,766 shares of the company's stock after acquiring an aNovember 15, 2024 | marketbeat.comAkero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024November 15, 2024 | globenewswire.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Down 19.1% in OctoberAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) saw a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 3,820,000 shares, a decrease of 19.1% from the October 15th total of 4,720,000 shares. Based on an average trading volume of 512,300 shares, the days-to-cover ratio is presently 7.5 days.November 15, 2024 | marketbeat.comHC Wainwright Expects Lower Earnings for Akero TherapeuticsNovember 15, 2024 | americanbankingnews.comHC Wainwright Has Negative Outlook of AKRO FY2024 EarningsAkero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) - Equities research analysts at HC Wainwright cut their FY2024 earnings per share estimates for shares of Akero Therapeutics in a report released on Monday, November 11th. HC Wainwright analyst E. Arce now anticipates that the company will earnNovember 14, 2024 | marketbeat.comAkero Therapeutics' (AKRO) Buy Rating Reiterated at HC WainwrightNovember 14, 2024 | americanbankingnews.comAkero Therapeutics to Present at the Jefferies London Healthcare ConferenceNovember 13, 2024 | globenewswire.comHC Wainwright Has Strong Estimate for AKRO FY2028 EarningsAkero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) - Research analysts at HC Wainwright raised their FY2028 earnings per share estimates for Akero Therapeutics in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst E. Arce now expects that the compaNovember 13, 2024 | marketbeat.comAkero Therapeutics price target raised to $35 from $30 at BofANovember 13, 2024 | markets.businessinsider.comBank of America Securities Reaffirms Their Hold Rating on Akero Therapeutics (AKRO)November 13, 2024 | markets.businessinsider.comAkero Therapeutics Reports Third Quarter 2024 Financial Results and Business UpdateAkero Therapeutics, Inc. made significant strides in the third quarter of 2024, announcing the dosing of the first patient in the Phase 3 SYNCHRONY Outcomes study of iNovember 12, 2024 | americanbankingnews.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Given Consensus Rating of "Moderate Buy" by BrokeragesNovember 11, 2024 | americanbankingnews.comAkero Therapeutics: Promising Pipeline and Strong Financial Position Suggest Favorable Risk/Reward ProfileNovember 10, 2024 | markets.businessinsider.comAkero Therapeutics (NASDAQ:AKRO) Releases Quarterly Earnings Results, Misses Expectations By $0.17 EPSAkero Therapeutics (NASDAQ:AKRO - Get Free Report) released its quarterly earnings data on Friday. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17).November 9, 2024 | marketbeat.comAkero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 9, 2024 | finance.yahoo.comBuy Rating Reaffirmed for Akero Therapeutics: Strong Financials and Promising Clinical Trials Bolster ConfidenceNovember 9, 2024 | markets.businessinsider.comAkero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 8, 2024 | globenewswire.comAkero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 50,716 SharesNovember 6, 2024 | insidertrades.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Recommendation of "Moderate Buy" from AnalystsAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy ratinNovember 6, 2024 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $1,601,104.12 in StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) COO Jonathan Young sold 50,716 shares of the business's stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $31.57, for a total value of $1,601,104.12. Following the completion of the sale, the chief operating officer now owns 216,286 shares of the company's stock, valued at $6,828,149.02. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.November 5, 2024 | marketbeat.comabrdn plc Sells 75,879 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)abrdn plc reduced its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 38.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 123,358 shares of the company's stock after selling 75,879 shares during the quarter. abrdn plc owned aNovember 4, 2024 | marketbeat.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 4,515 Shares of StockNovember 2, 2024 | insidertrades.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 15,485 SharesNovember 2, 2024 | insidertrades.comNotice to Akero Therapeutics, Inc. (AKRO) Shareholders: Grabar Law Office Is Investigating Claims of Misconduct on Your BehalfNovember 1, 2024 | markets.businessinsider.comAkero Therapeutics (NASDAQ:AKRO) Trading 5.8% Higher - Time to Buy?Akero Therapeutics (NASDAQ:AKRO) Shares Up 5.8% - Time to Buy?October 29, 2024 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Down 30.3% in OctoberAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) saw a significant decrease in short interest in the month of October. As of October 15th, there was short interest totalling 4,720,000 shares, a decrease of 30.3% from the September 30th total of 6,770,000 shares. Based on an average daily trading volume, of 500,300 shares, the days-to-cover ratio is presently 9.4 days.October 27, 2024 | marketbeat.comAkero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024October 21, 2024 | globenewswire.comAkero Therapeutics (NASDAQ:AKRO) Stock, Short Interest ReportOctober 21, 2024 | benzinga.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Sells 24,992 Shares of StockOctober 19, 2024 | insidertrades.comRheos Capital Works Inc. Raises Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Rheos Capital Works Inc. grew its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 27.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 276,000 shares of the company's stock after buying an additional 60,000 shares during the period. RheoOctober 17, 2024 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 6,136 SharesOctober 17, 2024 | insidertrades.comJonathan Young Sells 40,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockOctober 17, 2024 | insidertrades.comAkero Therapeutics (AKRO): Leading the Charge in MASH Treatment with EfruxiferminOctober 17, 2024 | msn.comAkero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge FundsOctober 16, 2024 | insidermonkey.comMillennium Management LLC Reduces Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Millennium Management LLC reduced its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 78.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 169,591 shares of the company's stock afOctober 14, 2024 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Given Average Rating of "Moderate Buy" by AnalystsAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the cOctober 12, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Grows Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO)The Manufacturers Life Insurance Company lifted its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 26.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 107,172 shares of the companyOctober 10, 2024 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Stock Price Up 4.2% - Still a Buy?Akero Therapeutics (NASDAQ:AKRO) Stock Price Up 4.2% - Here's What HappenedOctober 8, 2024 | marketbeat.comJonathan Young Sells 10,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockOctober 4, 2024 | insidertrades.com Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost. To claim your copy free of charge simply follow this link. AKRO Media Mentions By Week AKRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKRO News Sentiment▼0.330.46▲Average Medical News Sentiment AKRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKRO Articles This Week▼237▲AKRO Articles Average Week Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Enanta Pharmaceuticals News Roivant Sciences News Ascendis Pharma A/S News Legend Biotech News Elanco Animal Health News Cytokinetics News Blueprint Medicines News Nuvalent News Viking Therapeutics News Lantheus News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKRO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKRO Stock Alerts